Literature DB >> 23145005

Gamma-glutamyltransferase level and risk of hypertension: a systematic review and meta-analysis.

Cun-Fei Liu1, Yu-Ting Gu, Hai-Ya Wang, Ning-Yuan Fang.   

Abstract

BACKGROUND: Several prospective observational studies suggest that gamma-glutamyltransferase(GGT) level is positively associated with risk of hypertension. However, these studies draw inconsistent conclusions. Therefore, we conducted a systematic review and meta-analysis to evaluate the exact association between GGT level and subsequent development of hypertension.
METHODS: We searched Pubmed, Embase, and Science Citation Index (ISI Web of Science) for prospective cohort studies examining the association between GGT level and hypertension. Then, pooled effect estimates (RRs) for the association between GGT level and hypertension were calculated.
RESULTS: A total of 13 prospective cohort studies including 43314 participants and 5280 cases of hypertension were included. The pooled RR of hypertension was 1.94(95%CI: 1.55-2.43; P<0.001) when comparing the risk of hypertension between the highest versus lowest category of GGT levels. Moreover, the risk of hypertension increased by 23% (summary RR: 1.23; 95%CI: 1.13-1.32; P<0.001) per 1 SD logGGT increment. Subgroup analyses showed significant positive associations in each subgroup except in ≧160/95 subgroup (RR: 2.56, 95%CI: 0.87-7.54; P = 0.088) and nondrinkers subgroup (RR: 1.76, 95%CI: 0.88-3.53; P = 0.113). Sensitivity analyses showed no single study significantly affects the pooled RRs. No publication bias was found in our meta-analysis.
CONCLUSIONS: GGT level is positively associated with the development of hypertension. Further studies are needed to confirm our findings and elucidate the exact mechanisms between GGT level and the incidence of hypertension.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23145005      PMCID: PMC3492247          DOI: 10.1371/journal.pone.0048878

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Gamma-glutamyltransferase(GGT) is a common biomarker of liver injury and alcohol consumption [1]. However, recent epidemiologic and clinical studies have also found a close association between GGT level and risk of cardiovascular disease, diabetes, and metabolic syndrome [2], [3], [4]. The relationships between them were further strengthened by published meta-analyses [5], [6], [7]. In the past twenty years, the association between GGT and risk of hypertension has been deeply investigated in cross-sectional and longitudinal studies [8]–[20]. However, these studies drew inconsistent, even opposite conclusions. For example, Kim et al [17] found a significant association between GGT quartiles and hypertension only in the drinkers and non-overweight subgroups, while Stranges et al [15] showed that higher GGT level increased the risk of hypertension in both noncurrent and current drinkers. Because of these inconsistent findings, we therefore conducted a systematic review and meta-analysis to attempt to solve the problem.

Methods

Search Strategy

The Pubmed, Embase, and Science Citation Index (ISI Web of Science) databases were searched to collect all publications on the association between GGT and hypertension (last search update: 15th June 2012) without language restriction. The following search terms were used: (Gamma-glutamyltransferase[MeSH] OR Gamma-glutamyltransferase[All Fields] OR gamma-GT[All Fields] OR GGT[All Fields] OR GGTP[All Fields]) AND (Hypertension[MeSH] OR Hypertension [All Fields] OR “Essential Hypertension”[All Fields] OR “Primary Hypertension”[All Fields] OR “High blood pressure”[All Fields]. Similar search terms were applied to Embase and the Science Citation Index. Moreover, reference lists were further retrieved from published articles to avoid missing any relevant studies. Our meta-analysis was performed according to the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines [21].

Study selection

Studies were included if they satisfied the following criteria: 1) the study design should be a prospective design; 2) GGT level in baseline was reported and hypertension as the outcome of interest; 3) the relative risk(RR) or odds ratio(OR) with 95% confidence intervals(CIs) were provided or obtained by calculation.

Data extraction

Two authors extracted information independently and disagreements were resolved by discussion and consensus. The following data were extracted from each included article: name of the first author, year of publication, country of origin, mean age of the populations, gender component, numbers of participants and cases, durations of follow-up, diagnostic criteria for ascertainment of hypertension, most fully adjusted effect estimates from multivariable for the highest versus the lowest group of GGT level with corresponding 95%CI and study-specific adjusted confounding factors. When the effect estimates of the same population were reported in different follow-up durations, we only included the data with the longest follow-up time.

Statistical analysis

Relative risk (RR) and 95% CI were chosen as the effect estimate to assess the association between GGT and hypertension. We calculated the combined RR and 95%CI using the most-adjusted RRs(by comparing the highest versus lowest category of GGT level). Heterogeneity among studies was examined by using chi-square-based Q test and I2 test. When significant heterogeneity (P value<0.05 and I2>50%) was detected, the pooled RR and 95%CI would be estimated in a random-effect model. Otherwise, a fixed-effect model was chosen. Subgroup analyses were further carried out by race/ethnicity, sex, sample sizes, durations of follow-up, definition of hypertension and number of adjusted confounding factors. In addition, we also analyzed combined RR per 1 SD (standard deviation) logGGT increment in three studies which presented their results (RRs) in per 1 SD logGGT increment. A sensitivity analysis was performed to evaluate whether the results were markedly affected by a single study. Publication bias was evaluated with Begg's and Egger's test, with a P value >0.05 considered as no significant. All statistical analyses were conducted with Stata software, version 11.0 (Stata Corp, College Station, Texas, USA). A P value<0.05 was considered statistically significant.

Results

Literature search

The flow diagram of literature search was shown in Figure 1. 1469 potentially relevant articles were initially identified. Of the 1469 articles identified, 1443 papers were excluded based on titles and abstracts. The remaining 26 articles were then further evaluated by reviewing full text. 13 studies were excluded due to the following reasons: 7 studies not a prospective design, 2 studies repeated with included studies, and 4 studies focused on the change of GGT over time with blood pressure. Finally, 13 articles [8]–[20] were included in our meta-analysis.
Figure 1

Flow diagram of included studies of meta-analysis.

Study characteristics

Thirteen prospective cohort studies involving 43314 participants and 5280 cases of hypertension were included in our meta-analysis. The characteristics of the 13 articles were summarized in Table 1. Among 13 studies, 10 studies were conducted in Asia, 2 in North-America, and 1 in Europe. The durations of follow-up ranged from 3 to 15 years. As to diagnosis of hypertension, hypertension was defined as blood pressure ≧160/95 mmHg, 140/90 mmHg, 130/85 mmHg and/or taking antihypertensive medications. Twelve studies including 15 data points (as 3 studies provided their results for men and women separately) offered the RRs and 95%CIs of highest versus lowest category of GGT level. Moreover, three studies [12], [16], [20] reporting their results in per 1 SD logGGT increment were exclusively analyzed.
Table 1

Characteristics of studies included in meta-analysis.

StudyCountryCase/Total [age(y)]Gender M/FDefinition of HypertensionFollow-up (years)Comparison (Highest vs Lowest, U/L)Adjusted RR(95%CI)Adjustment for covariates
Yamada [11]; 1991Japan29/1393 (35–54)1393/0≧160/955≧50 vs <504.52(2.17–9.40)None
Miura [20], 1994Japan36/77 (30–69)77/0≧140/90, meds10≧20 vs <105.82(1.83–18.56)Age, SBP, DBP, alcohol consumption.
Per 1 SD logGGT increment1.41(1.09–1.83)
Lee [14], 2002Korea169/8170 (25–50)8170/0≧160/95, meds4≧50 vs ≦91.5(0.8–2.8)Age, BMI, smoking, drinking, exercise, family history of hypertension, SBP or DBP, the change of BMI, drinking during four years.
Lee [13], 2003USA708/4704 (18–30)NA≧140/90, meds15>36 vs ≦121.5(1.0–2.2)Age, sex, race, study center, BMI, alcohol consumption, cigarette smoking, physical activity, systolic blood pressure, insulin.
Stranges [15], 2005USA195/897 (39–79)587/310≧140/90, meds6(39–55) vs ≦142.1(1.1–4.0)Age, gender, race, average of alcohol, smoking status, BMI, physical activity, systolic blood pressure.
Ander [10], 2007France492/2273 (NA)1129/1144≧130/85, meds3M: ≧49.4 vs <19.7; F: ≧23 vs <12.6M:1.76(1.06–2.92); F:1.38(0.87–2.20)Age
Jo [9], 2009Korea2170/17281 (NA)11659/5622≧130/85, meds4M:>38 vs <19; F:>15 vs <9M:2.44(2.07–2.88); F:1.49(1.14–1.94)Age
Jimba [18], 2009Japan288/1027 (49±8)NA≧130/85, meds3≧42 vs ≦241.15(0.76–1.73)Age, sex, alcohol habit, BMI
Hwang [19], 2010Korea83/293 (54.1±8.9)115/176≧140/90, meds5M: >46 vs <17; F: >19 vs <9M:0.5(0.1–2.8); F:7.8((2.4–25.0)Age, education, BMI, alcohol intake, cigarette smoking, exercise, salt intake, family history of hypertension, ALT
Cheung [16], 2011China126/708 (47.3±9.7)428/280≧140/90, meds5.3M: ≧31 vs ≦20; F: ≧20 vs ≦132.68(1.36–5.26)Age, sex, systolic blood pressure at baseline, follow-up duration, BMI, triglycerides, HDL cholesterol, HOMA-IR, CRP, fibrinogen, current smoking, change in BMI
Per 1 SD logGGT increment1.38(1.05–1.81)
Xu [8], 2011China119/285 (NA)NA≧130/85, meds3.5(41–68) vs <161.55(0.72–3.31)Age, sex
Onat [12], 2012Turkey476/1423 (33–84)735/678≧140/90, meds4Per 1 SD logGGT increment1.20(1.10–1.31)Age, sex, menopause, BMI, alcohol usage
Kim [17], 2012Korea389/4783 (44±5.8)3246/1537≧140/90, meds3(29–51) vs ≦12.92.638(1.259–5.528)Age, sex, alcohol amount, smoking status, physical activity, BMI, baseline glucose, uric acid, HDL, LDL, TG, Hs-CRP, baseline systolic blood pressure

Abbreviations: NA: not applicable; M, Man; F, Female; BMI, body mass index; ALT, alanine aminotransferase; HOMA-IR, homeostasis model assessment index of insulin resistance; CRP, C-reactive protein; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; TG, triglyceride.

Abbreviations: NA: not applicable; M, Man; F, Female; BMI, body mass index; ALT, alanine aminotransferase; HOMA-IR, homeostasis model assessment index of insulin resistance; CRP, C-reactive protein; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; TG, triglyceride.

Meta-analysis

As is shown in Figure 2, the pooled RR of hypertension was 1.94(95%CI: 1.55–2.43; P<0.001) for the highest versus lowest category of GGT level; statistical heterogeneity was found in the study results (Q = 40.29, P = 0.000, I2 = 65.3%).
Figure 2

Meta-analysis of risk of hypertension between highest vs lowest category of GGT.

As above, three studies [12], [16], [20] provided their results in per 1 SD logGGT increment. Overall, risk of hypertension increased by 23% (summary RR: 1.23; 95%CI: 1.13–1.32; P<0.001) per 1 SD logGGT increments without evident heterogeneity (Q = 1.82, P = 0.403, I2 = 0%).

Subgroup and sensitivity analyses

The effects of GGT level on risk of hypertension in different subgroups are shown in Table 2. Overall, the positive association between GGT level and risk of hypertension was consistently observed in each subgroup except in ≧160/95 subgroup (RR: 2.56, 95%CI: 0.87–7.54; P = 0.088) and nondrinkers (RR: 1.76, 95%CI: 0.88–3.53; P = 0.113).
Table 2

Subgroup analyses of GGT level and risk of hypertension.

GroupNumber of studiesRR(95%CI)P value for effect estimatesP value for heterogeneityI2(%)
All studies15a1.94(1.55–2.44)<0.001<0.00165.3
Race/ethnicity
Asians112.14(1.58–2.90)<0.001<0.00171.6
Non-Asians41.59(1.25–2.03)<0.0010.7270
Gender
Men only62.29(1.56–3.37)<0.0010.03358.8
Women only31.91(1.06–3.43)0.0310.02273.8
Both men and women61.70(1.28–2.24)<0.0010.20331.0
Drinking status
Nondrinkers51.76(0.88–3.53)0.1130.13642.8
Drinkers42.39(1.29–4.44)0.0060.05161.4
Durations, y
≤5111.87(1.42–2.45)<0.001<0.00170.8
>542.23(1.40–3.53)0.0010.11050.2
Sample size
≤100052.86(1.48–5.54)0.0020.05357.2
>1000101.77(1.39–2.24)<0.0010.00167.8
Definition of HBP
≧160/9522.56(0.87–7.54)0.0880.02580.1
≧140/90,72.44(1.54–3.86)<0.0010.02658.1
>130/8561.63(1.21–2.18)0.0010.00174.9
Adjustment for covariates
≤5 factors81.90(1.40–2.57)<0.001<0.00175.3
>5 factors72.05(1.40–3.00)<0.0010.06649.2

a: twelve studies including 15 data points.

a: twelve studies including 15 data points. To evaluate the impact of single studies on the combined results, we conducted sensitivity analyses by omitting one study at a time and reassessed the summary RR for the remaining studies. As is shown in Figure 3, no single study significantly affects the pooled RRs
Figure 3

Sensitivity analyses results of given named study omitted.

Publication bias

Begg's and Egger's test were performed to test if there was publication bias. As is shown in Figure 4, no publication bias was found (Egger' test: P = 0.952)
Figure 4

Begg' funnel plot analysis of publication bias.

Discussion

Recent studies suggested that GGT was a novel biomarker of cardiovascular risk. As to the relationship between GGT and hypertension, previous studies have drawn inconsistent conclusions. In this study, we comprehensively evaluated the exact association between GGT level and risk of hypertension. Our present systematic review and meta-analysis of 13 prospective studies showed a significant positive association between GGT level and risk of hypertension (RR: 1.94, 95%CI: 1.55–2.43). Moreover, our results also showed that risk of hypertension increased by 23% (95%CI: 1.13–1.32) per 1 SD logGGT increment. Subgroup analyses showed that the positive association between GGT level and risk of hypertension consistently existed in each subgroup except in ≧160/95 subgroup (RR: 2.56, 95%CI: 0.87–7.54; P = 0.088) and nondrinkers subgroup (RR: 1.76, 95%CI: 0.88–3.53; P = 0.113). In our subgroup analyses, an interesting phenomenon was observed: the positive association between GGT level and risk of hypertension was more significant in Asians and male subgroups than that in non-Asians and female subgroups. As is commonly known, Asians have more prevalence of hepatic diseases such as hepatitis B or C, while men are more prone to drink alcoholic beverages. Accordingly, subgroup analysis in nondrinkers showed an increased trend but did not reach a statistical significance (RR: 1.76, 95%CI: 0.88–3.53; P = 0.113). Therefore, although most studies in our meta-analysis have adjusted alcohol habits or liver diseases, the possibility that the positive association of GGT and risk of hypertension is explained by alcohol consumption or liver diseases is not completely excluded. However,three studies [15], [17], [19] performed within normal range of GGT levels showed that relative risk is still much higher in highest category of normal range of GGT levels than that in lowest category (RR: 2.44, 95%CI: 1.15–5.20; P = 0.021). Hence, further prospective studies with much more strict inclusion criteria should be conducted to evaluate a more accurate relationship between GGT level and the development of hypertension. Exact mechanisms that link GGT with hypertension are not fully elucidated, however, several possible explanations are as follows: Longitudinal study showed that GGT is positively associated with inflammation markers such as fibrinogen, C–reactive protein and F2-isoprostanes [13]. In addition, a study found that GGT was expressed in human atherosclerotic lesions colocalizing with ox-LDL and foam cells, which could contribute to the progression of atherosclerosis [22]. Lastly, GGT plays an important role in the generation of free radical species through its interaction with iron [23]. Base on the above findings, elevated GGT level could be a marker of inflammation condition and oxidative stress, which were important features of hypertension. Several limitations in our study should be pointed out. First, although most included studies have adjusted for a series of potential confounders, the possibility of residual or unknown confounding still can not be completely excluded. Second, several studies included in our meta-analysis did not specifically exclude subjects with hepatic diseases or alcohol abuse at baseline, this may confuse the true association of GGT with hypertension as liver damage and alcohol intake could affect GGT levels. However, studies that investigated only in nondrinkers [16] or participants without hepatitis [17] and within normal range of GGT levels [15], [17], [19] also found a positive association between GGT level and risk of hypertension. Third, moderate heterogeneity was observed in our meta-analysis, which is not surprising because of methodological variations, including study population, different ranges of exposure, and number of adjustment factors among studies. To find out source of heterogeneity, we conducted a meta-regression analysis. Regrettably, we did not detect the source of heterogeneity (data not shown). Finally, publication bias may existed for studies with null results as these tend not to be published. However, we did not find evidence of publication bias in our meta-analysis. In conclusion, our study suggests that GGT level is independently associated with the development of hypertension. However, further studies are needed to confirm our findings and elucidate the exact mechanisms between GGT and the incidence of hypertension.
  23 in total

1.  Body fat distribution, liver enzymes, and risk of hypertension: evidence from the Western New York Study.

Authors:  Saverio Stranges; Maurizio Trevisan; Joan M Dorn; Jacek Dmochowski; Richard P Donahue
Journal:  Hypertension       Date:  2005-10-03       Impact factor: 10.190

2.  Serum gamma-glutamyl transferase level is an independent predictor of incident hypertension in Korean adults.

Authors:  Nan Hee Kim; Jung Kwon Huh; Byung Jin Kim; Min Woong Kim; Bum Soo Kim; Jin Ho Kang
Journal:  Clin Exp Hypertens       Date:  2012-04-03       Impact factor: 1.749

3.  Gamma-glutamyltransferase, alcohol, and blood pressure. A four year follow-up study.

Authors:  Duk-Hee Lee; Myung-Hwa Ha; Jang-Rak Kim; Myron Gross; David R Jacobs
Journal:  Ann Epidemiol       Date:  2002-02       Impact factor: 3.797

4.  Alcohol, high blood pressure, and serum gamma-glutamyl transpeptidase level.

Authors:  Y Yamada; M Ishizaki; T Kido; R Honda; I Tsuritani; E Ikai; H Yamaya
Journal:  Hypertension       Date:  1991-12       Impact factor: 10.190

Review 5.  Gamma glutamyl transferase.

Authors:  J B Whitfield
Journal:  Crit Rev Clin Lab Sci       Date:  2001-08       Impact factor: 6.250

Review 6.  Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.

Authors:  D F Stroup; J A Berlin; S C Morton; I Olkin; G D Williamson; D Rennie; D Moher; B J Becker; T A Sipe; S B Thacker
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

7.  Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study.

Authors:  Duk-Hee Lee; David R Jacobs; Myron Gross; Catarina I Kiefe; Jeffrey Roseman; Cora E Lewis; Michael Steffes
Journal:  Clin Chem       Date:  2003-08       Impact factor: 8.327

Review 8.  Is serum gamma glutamyltransferase a marker of oxidative stress?

Authors:  Duk-Hee Lee; Rune Blomhoff; David R Jacobs
Journal:  Free Radic Res       Date:  2004-06

9.  Serum gamma-glutamyl transferase level in predicting hypertension among male drinkers.

Authors:  K Miura; H Nakagawa; H Nakamura; M Tabata; H Nagase; M Yoshida; S Kawano
Journal:  J Hum Hypertens       Date:  1994-06       Impact factor: 3.012

10.  Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men.

Authors:  Noriyuki Nakanishi; Kenji Suzuki; Kozo Tatara
Journal:  Diabetes Care       Date:  2004-06       Impact factor: 19.112

View more
  27 in total

Review 1.  Gamma-glutamyl transferase and cardiovascular disease.

Authors:  Gjin Ndrepepa; Adnan Kastrati
Journal:  Ann Transl Med       Date:  2016-12

2.  Association between serum γ-glutamyltransferase and chronic kidney disease in urban Han Chinese: a prospective cohort study.

Authors:  Zhen-Wei Shen; Jie Xing; Qing-Lian Wang; Ali Faheem; Xiang Ji; Jie Li; Wei-Wei Bian; Zheng Jiang; Xiu-Jun Li; Fu-Zhong Xue; Jing Liu
Journal:  Int Urol Nephrol       Date:  2016-10-04       Impact factor: 2.370

3.  Fasting glucose and HbA1c levels as risk factors for the development of hypertension in Japanese individuals: Toranomon hospital health management center study 16 (TOPICS 16).

Authors:  Y Heianza; Y Arase; S Kodama; S D Hsieh; H Tsuji; K Saito; S Hara; H Sone
Journal:  J Hum Hypertens       Date:  2014-09-18       Impact factor: 3.012

4.  Ramadan fasting in Saudi Arabia is associated with altered expression of CLOCK, DUSP and IL-1alpha genes, as well as changes in cardiometabolic risk factors.

Authors:  Ghada M A Ajabnoor; Suhad Bahijri; Noor Ahmad Shaik; Anwar Borai; Aliaa A Alamoudi; Jumana Y Al-Aama; George P Chrousos
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

5.  Liver-function parameters are associated with incident hypertension in a large Taiwanese population follow-up study.

Authors:  Yi-Hsueh Liu; Szu-Chia Chen; Wen-Hsien Lee; Ying-Chih Chen; Jiun-Chi Huang; Pei-Yu Wu; Chih-Hsing Hung; Chao-Hung Kuo; Ho-Ming Su
Journal:  J Hum Hypertens       Date:  2022-05-26       Impact factor: 3.012

6.  Liver enzymes and risk of ocular motor cranial nerve palsy: a nationwide population-based study.

Authors:  Joonhyoung Kim; Kyungdo Han; Juhwan Yoo; Kyung-Ah Park; Sei Yeul Oh
Journal:  Neurol Sci       Date:  2021-11-23       Impact factor: 3.830

7.  An association between serum γ-glutamyltransferase and proteinuria in drinkers and non-drinkers: a Japanese nationwide cross-sectional survey.

Authors:  Toshihiro Ishigami; Ryohei Yamamoto; Yasuyuki Nagasawa; Yoshitaka Isaka; Hiromi Rakugi; Kunitoshi Iseki; Kunihiro Yamagata; Kazuhiko Tsuruya; Hideaki Yoshida; Shouichi Fujimoto; Koichi Asahi; Issei Kurahashi; Yasuo Ohashi; Toshiki Moriyama; Tsuyoshi Watanabe
Journal:  Clin Exp Nephrol       Date:  2014-02-04       Impact factor: 2.801

8.  Associations between total serum GGT activity and metabolic risk: MESA.

Authors:  Ryan Bradley; Annette L Fitzpatrick; Nancy S Jenny; Duk-Hee Lee; David R Jacobs
Journal:  Biomark Med       Date:  2013-10       Impact factor: 2.851

9.  Quantitative analysis of γ-glutamylisoleucine, γ-glutamylthreonine, and γ-glutamylvaline in HeLa cells using UHPLC-MS/MS.

Authors:  Jonathan B Thacker; Chenchen He; Subramaniam Pennathur
Journal:  J Sep Sci       Date:  2021-06-13       Impact factor: 3.614

10.  Body mass index and metabolic factors predict glomerular filtration rate and albuminuria over 20 years in a high-risk population.

Authors:  Gabriele Nagel; Emanuel Zitt; Raphael Peter; Alfonso Pompella; Hans Concin; Karl Lhotta
Journal:  BMC Nephrol       Date:  2013-08-20       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.